Just 5 years after its first demonstration as a genome editing tool, CRISPR is pretty much a household name. From its humble beginnings as a way for bacteria to chop up invading viral DNA, CRISPR has taken over our discussions of animal models, high-throughput screens, GMOs, and gene therapy-even biomedical ethics and scientific patent law-all at breakneck speed. While CRISPR is not without its drawbacks, it has major advantages in that it is programmable and applicable to countless organisms, cell types, and research questions. With over 2,500 CRISPR papers published already in 2018, it's easy to wonder whether there is anything truly new left under the sun.
With CRISPR-mediated genome editing, the CRISPR enzyme makes a cut at the site specified by its guide RNA, and cellular repair processes take over to fix the DNA lesion, often introducing small insertions and deletions or stimulating homologous recombination at the site. This process leads to editing of the DNA sequence, allowing scientists to create point mutations; engineer nucleotide substitutions in regulatory regions; insert tags or reporter genes; or delete exons, genes, or sets of genes, for example. Now, two studies from the labs of Zhongjun Qin and Jef Boeke push the technology to its limits by using CRISPR to fuse entire yeast chromosomes together. Qin and colleagues took advantage of yeast's superior homologous recombination efficiency to create one single, fused chromosome out of the native 16. Remarkably, the single-chromosome yeast cells had very similar cell growth and transcriptome to wild-type yeast (Shao et al., 2018) . In the study by Boeke and colleagues, the authors fused yeast chromosomes to create a two-chromosome yeast strain that is reproductively isolated from wild-type yeast, opening up the question of whether it can be classified as a separate species. Similar to the related paper, they also observed that the yeast cells with this drastically altered karyotype were viable with only slightly reduced growth rate (Luo et al., 2018) . Moving CRISPR technology from gene editing to karyotype engineering holds promise to investigate fundamental questions in telomere and centromere biology, meiosis, speciation, and aneuploidy.
Many of the technological innovations we've seen in the CRISPR world stem from its use as a sequence-specific DNA binding protein in the absence of cutting. A couple amino acid substitutions in the catalytic centers of the CRISPR enzyme and all of a sudden you have a module to recruit essentially anything you want to a particular location in the genome. Early work establishing this platform led to widely used technologies like CRISPRi and CRISPRa and, more recently, base editing. Turning up or down gene expression, changing epigenetic marks, recruiting transcription factors or fluorescent markers . . . it's hard to imagine what hasn't yet been done with CRISPR-until someone does it. A new paper by John Dueber and colleagues presents EvolvR, a CRISPR-based technology for targeted hypermutation and experimental evolution studies. The technique uses CRISPR-guided nickases to localize an error-prone DNA polymerase to specific endogenous or exogenous loci of interest. This approach led to nearly seven orders of magnitude increased mutation frequency in CRISPR-specified genomic windows of up to 350 base pairs, which can also be multiplexed to simultaneously mutate more than one region in the genome (Halperin et al., 2018) . Continuous sequence diversification of targeted loci is a major advance that paves the way for evolving new enzymatic activities, mapping drug targets and protein-protein interaction interfaces, and providing a barcode or ''clock'' for cellular lineage tracing.
While we may think of CRISPR as primarily a cut-and-paste tool for the genome, several groups have recently developed its utility as a search tool. These new applications in CRISPRbased diagnostics stem from fundamental biochemical discoveries about the properties of some more recently discovered CRISPR effector enzymes, Cas12 and Cas13. Unlike the more famous Cas9, both of these enzymes are activated by a target sequence matching their guide RNA to then unleash a potent, non-specific, and multi-turnover nucleic acid cleavage activity. Cas12a recognizes a double-stranded DNA target and displays ''collateral'' cleavage against singlestranded DNA, whereas Cas13a acts on single-stranded RNA for both target-and non-specific activities.
While this collateral activity may seem like a disadvantage for programmable editing applications with these effectors, it turns out that it can be harnessed as a powerful tool to report on nucleic acid detection. Based on principles first described by the labs of Feng Zhang and Jennifer Doudna, these diagnostic tools rely on activation of the CRISPR effector in the presence of a guide RNA-specified sequence, coupled with robust collateral cleavage activity against a reporter oligonucleotide that can be detected through fluorescence or other means when cut. Building on their previous work with Cas13-based RNA detection, Doudna and colleagues recently reported the development of Cas12a for DNA sequence detection, developing a sensitive system for attomolar detection of human papillomavirus in patient samples (Chen et al., 2018) . Recent work from the Zhang lab achieved multiplexed, orthogonal detection of up to four target sequences simultaneously, including Dengue and Zika virus, also at attomolar concentrations. Looking forward to the potential for broad utility outside of the laboratory setting, the group modified their design from a fluorescent reporter to a colorimetric reporter that can be detected on a lateral flow strip (think: pregnancy test) . Pardis Sabeti and colleagues reported the rapid development and use of lateral flow strip-based diagnostics to detect dengue, Zika, yellow fever, and West Nile viral RNA directly from human urine, blood, serum, or saliva. The platform is also able to identify virus variants, potentially providing a means to quickly diagnose virulence-associated or drug resistance mutations in an outbreak (Myhrvold et al., 2018) . These exciting innovations provide extremely fast and sensitive diagnostics that can be rapidly developed for virtually any new RNA-or DNA-based pathogen that arises and deployed in the field without the need for laboratory equipment. CRISPR-based diagnostics may also replace existing slow and cumbersome hospital tests for common genetic variants, such as cancer liquid biopsies , expanding their utility far beyond infectious disease.
With innovative minds from so many fields and disciplines diving into the CRISPR world, the sky is the limit for dreaming up new and inventive CRISPR-based technologies. There is no doubt that these advances will continue accelerating the pace of discovery, expanding CRISPR's reach to new frontiers and pushing the boundaries of what is possible in biology, agriculture, engineering, and medicine.
